Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections

NCT07456826

Status	RECRUITING
Phase	Phase 4
Sponsor	Harrow Inc
Enrollment	236 participants

Key Eligibility Criteria

Inclusion (7)

- Able to understand and voluntarily provide written informed consent prior to initiation of any study-specific procedures
- Male or female, age e 18 years
- Scheduled to undergo unilateral, uncomplicated intravitreal injection of an FDA-approved, non-biosimilar anti-VEGF agent in the study eye
- Diagnosis requiring anti-vascular endothelial growth factor (anti-VEGF) treatment, including macular edema (cystoid or diabetic), retinal vein occlusion, diabetic retinopathy, or neovascular age-related macular degeneration
- At least three prior intravitreal anti-VEGF injections in the study eye

... and 2 more (see full listing online)

Exclusion (20)

- Scheduled to undergo simultaneous bilateral intravitreal injection
- Pre-existing eye pain in the study eye
- Fewer than three prior intravitreal anti-VEGF injections in the study eye within 365 days prior to enrollment
- Mental disability or cognitive impairment that prevents reliable pain assessment
- Prisoner

... and 15 more (see full listing online)

Locations (1 total)

Tyler Retina Research Institute, Tyler, Texas, United States